Oncolytics Biotech Inc (ONCY) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Oncolytics Biotech reported revenue of $0. Net income was -$28.8M, or -$0.30 per diluted share. Operating activities generated -$20.1M of cash, leaving -$20.1M of free cash flow. At fiscal year end, Oncolytics Biotech held $7.6M in total assets against $11.4M in total liabilities, including $5.2M of cash and equivalents.
Open the full interactive Oncolytics Biotech financials → Quarterly statements, key ratios, valuation history and price charts.
Oncolytics Biotech Key Stats
| Share Price | $0.49 |
|---|---|
| Market Cap | $58.7M |
| 52-Week Range | $0.47 – $1.27 |
| Shares Outstanding | 119.7 million (basic, 2026 Q2) |
Oncolytics Biotech Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$28.7M |
| Pre-Tax Income | -$28.7M |
| Income Tax | $79,000 |
| Net Income | -$28.8M |
| Diluted EPS | -$0.30 |
Oncolytics Biotech Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | -$9.2M | -$9.4M |
| Diluted EPS | -$0.08 | -$0.08 |
Oncolytics Biotech Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $5.2M |
| Current Assets | $6.8M |
| Total Assets | $7.6M |
| Current Liabilities | $6.1M |
| Total Liabilities | $11.4M |
| Shareholders' Equity | -$3.8M |
Oncolytics Biotech Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$20.1M |
| Cash From Investing | -$6,000 |
| Cash From Financing | $14.1M |
| Free Cash Flow | -$20.1M |
Figures from Oncolytics Biotech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Oncolytics Biotech financials page for every line item.
Oncolytics Biotech Company Profile
| Ticker | ONCY |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001129928 |
Frequently Asked Questions
What was Oncolytics Biotech's revenue in fiscal 2025?
Oncolytics Biotech (ONCY) reported revenue of $0 for fiscal 2025.
What was Oncolytics Biotech's net income in fiscal 2025?
Oncolytics Biotech reported net income of -$28.8M for fiscal 2025.
What was Oncolytics Biotech's earnings per share (EPS) in fiscal 2025?
Oncolytics Biotech's diluted EPS was -$0.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Oncolytics Biotech generate in fiscal 2025?
Oncolytics Biotech generated -$20.1M of free cash flow in fiscal 2025.
What was Oncolytics Biotech's revenue last quarter?
In its most recent reported quarter (2026 Q2), Oncolytics Biotech reported revenue of $0.
How many shares of Oncolytics Biotech are outstanding?
Oncolytics Biotech reported a weighted average of 119.7 million basic shares outstanding in 2026 Q2.
What is Oncolytics Biotech's market cap?
Based on its latest closing price, Oncolytics Biotech (ONCY) has a market capitalization of about $58.7M.
When does Oncolytics Biotech's fiscal year end?
Oncolytics Biotech's fiscal year end, as registered with the SEC, is December 31.
Where is Oncolytics Biotech headquartered?
Oncolytics Biotech lists its business address in San Diego, California in its SEC filings.